ArriVent BioPharma: Its Leading Asset, Furmonertinib, Supports A Cautious Buy

ArriVent BioPharma's furmonertinib demonstrates robust efficacy, CNS penetration, and tolerability in early trials. Read why ...

40 Years On, Marvel Can Finally Deliver The Wildest Dream X-Men Movie That Never Was

Recent speculation has hinted that our wildest X-Men movie dreams might finally be coming true, thanks to one global ...